NASDAQ · PRTA
Prothena Corporation plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PRTA: Nov 5, 2026
Prothena Corporation plc Ordinary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.67.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.38 | $-0.37 | $-0.38 | 3 |
| Dec 2026 | $0.18 | $0.74 | $-0.38 | 2 |
| Mar 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Jun 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks- Fintel · 3 h agoBristol Myers Squibb to Terminate PRX019 Global License Agreement with Prothena Corporation plcFollowing an internal strategic review, Bristol Myers Squibb informed Prothena Corporation plc on October 28, 2026 that it has decided not to advance PRX019 further in the clinic. As a result, the PRX019 Global License Agreement will terminate on January 28, 2027. Under the agree
- Zacks · Oct 20, 11:34 AM EDTProthena's Partnership Strategy: Growth Driver or Limitation?PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.
- Zacks · Oct 8, 10:40 AM EDTCRMD vs. PRTA: Which Stock Should Value Investors Buy Now?CRMD vs. PRTA: Which Stock Is the Better Value Option?
- Zacks · Sep 21, 12:40 PM EDT4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayFour biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
- Zacks · Aug 14, 11:40 AM EDTKMDA or PRTA: Which Is the Better Value Stock Right Now?KMDA vs. PRTA: Which Stock Is the Better Value Option?
- Zacks · Aug 7, 1:41 PM EDTPRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in FocusProthena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
- Zacks · Aug 6, 7:10 PM EDTProthena (PRTA) Reports Q2 Loss, Misses Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 5:10 PM EDTVanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue EstimatesVanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 9, 11:38 AM EDTPRTA Stock Rises Nearly 11% in Six Months: What's Driving It?Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
- Zacks · Jun 24, 11:40 AM EDTSRPT or PRTA: Which Is the Better Value Stock Right Now?SRPT vs. PRTA: Which Stock Is the Better Value Option?
- Zacks · Jun 12, 5:44 AM EDTAdaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- Zacks · May 8, 10:36 AM EDTProthena Posts Q1 Earnings as Revenues Surge on Milestone PaymentPRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Prothena Corporation plc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.